Forum Financial Management LP Has $1.88 Million Position in Danaher Co. (NYSE:DHR)

Forum Financial Management LP increased its position in Danaher Co. (NYSE:DHR - Free Report) by 38.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 8,202 shares of the conglomerate's stock after purchasing an additional 2,282 shares during the period. Forum Financial Management LP's holdings in Danaher were worth $1,883,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. boosted its stake in Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate's stock worth $401,000 after purchasing an additional 42 shares during the period. Grimes & Company Inc. lifted its position in Danaher by 0.6% in the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate's stock worth $1,696,000 after buying an additional 43 shares in the last quarter. Spinnaker Trust lifted its position in Danaher by 1.2% in the 4th quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock worth $988,000 after buying an additional 50 shares in the last quarter. Fortis Capital Advisors LLC lifted its position in Danaher by 1.3% in the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after buying an additional 50 shares in the last quarter. Finally, Fayez Sarofim & Co lifted its position in Danaher by 0.6% in the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Activity

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DHR shares. Raymond James reiterated a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Wall Street Zen downgraded shares of Danaher from a "buy" rating to a "hold" rating in a research report on Saturday. Stifel Nicolaus upgraded shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price for the company in a research report on Friday, March 14th. Robert W. Baird cut their price target on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Finally, The Goldman Sachs Group cut their price target on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $263.24.

Danaher Stock Performance

DHR traded up $4.48 during trading on Tuesday, hitting $189.02. The stock had a trading volume of 2,990,603 shares, compared to its average volume of 3,473,399. The firm has a market cap of $135.28 billion, a PE ratio of 35.80, a P/E/G ratio of 2.66 and a beta of 0.80. The company has a 50 day simple moving average of $194.50 and a 200-day simple moving average of $214.85. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.68%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.